Tsang, Tawny
Naples, Adam J.
Barney, Erin C.
Xie, Minhang
Bernier, Raphael
Dawson, Geraldine
Dziura, James
Faja, Susan
Jeste, Shafali Spurling
McPartland, James C.
Nelson, Charles A.
Murias, Michael
Seow, Helen
Sugar, Catherine
Webb, Sara J.
Shic, Frederick http://orcid.org/0000-0002-9040-1259
Johnson, Scott P.
Funding for this research was provided by:
National Institutes of Health (NIMH U19 MH108206, NIMH K01 MH104739)
Article History
Accepted: 5 April 2022
First Online: 3 June 2022
Declarations
:
: Frederick Shic consults for Roche Pharmaceutical Company, Janssen Research and Development, BioStream LLC, and BlackThorn Therapeutics. James C. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, and Springer. Sara J. Webb consults for Janssen Research and Development. Dr. Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili Interactive, Inc, LabCorp, Inc, Roche Pharmaceutical Company, and Tris Pharma, and is a consultant to Apple, Gerson Lehrman Group, Guidepoint Global, Inc, and is CEO of DASIO, LLC. Dr. Dawson has stock interests in Neuvana, Inc. The authors Tawny Tsang, Adam Naples, Erin Barney, Minhang Xie, Raphael Bernier, James Dziura, Susan Faja, Shafli Jeste, Charles A. Nelson, Michael Murias, Helen Seow, Catherine Sugar, and Scott P. Johnson declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. No company contributed to funding of this study. A representative from Janssen served on the FNIH Biomarkers Consortium Project Team and provided in kind support in terms of sharing experiences and preliminary results of the JAKE study.